RxDoctor Payments Data

Summer Mitchell

Family · Jackson, MSNPI 1538558473

Payments from drug & device makers

$3,099in general payments, 2019–2025

Across 165 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Boehringer Ingelheim$683
  • AstraZeneca$261
  • Merck$225
  • Medtronic$202
  • Amgen$141
  • plus $584 from 17 others

What the payments were for

  • Food & beverage$3,04998%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,099 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$3,983
Medicare patients
59
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$87,246
EntrestoSacubitril/Valsartan46$39,464
JardianceEmpagliflozin23$28,845
BrilintaTicagrelor12$5,952
Ranolazine ErRanolazine21$1,656
Metoprolol Succinate143$1,316
Nifedipine ErNifedipine57$1,099
Atorvastatin Calcium70$531
ClopidogrelClopidogrel Bisulfate53$446
Amiodarone Hcl56$392
Carvedilol65$363
Amlodipine Besylate79$362
Valsartan43$320
Nitroglycerin18$242
Hydralazine Hcl23$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$87,24697 claims
NovartisEntresto$1,004$39,46446 claims
Boehringer IngelheimJardiance$683$28,84523 claims
AstraZenecaBrilinta$261$5,95212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →